Pemirolast
Clinical data | |
---|---|
Trade names | Alamast |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Oral, ophthalmic |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 69372-19-6 |
PubChem (CID) | 57697 |
IUPHAR/BPS | 7329 |
DrugBank | DB00885 |
ChemSpider | 51990 |
UNII | 2C09NV773M |
KEGG | D07476 |
ChEMBL | CHEMBL1201198 |
ECHA InfoCard | 100.222.995 |
Chemical and physical data | |
Formula | C10H8N6O |
Molar mass | 228.21 g/mol |
3D model (Jmol) | Interactive image |
| |
(what is this?) (verify) |
Pemirolast (INN) is a mast cell stabilizer used as an anti-allergic drug therapy. It is marketed under the tradenames Alegysal and Alamast.
It has also been studied for the treatment of asthma.
References
- Tinkelman DG, Berkowitz RB (February 1991). "A pilot study of pemirolast in patients with seasonal allergic rhinitis". Ann Allergy. 66 (2): 162–5. PMID 1994787.
- Kawashima T, Iwamoto I, Nakagawa N, Tomioka H, Yoshida S (1994). "Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils". Int. Arch. Allergy Immunol. 103 (4): 405–9. doi:10.1159/000236662. PMID 8130655.
- Abelson MB, Berdy GJ, Mundorf T, Amdahl LD, Graves AL (October 2002). "Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies". J Ocul Pharmacol Ther. 18 (5): 475–88. doi:10.1089/10807680260362759. PMID 12419098.
- Kemp JP, Bernstein IL, Bierman CW, et al. (June 1992). "Pemirolast, a new oral nonbronchodilator drug for chronic asthma". Ann Allergy. 68 (6): 488–91. PMID 1610024.
External links
- Mitsubishi Tanabe Pharma Corporation (2007). "ALEGYSAL (English)" (PDF). Retrieved 2008-09-02.
- "DailyMed Announcements". U.S. National Library of Medicine. 2005. Retrieved 2008-09-02.
This article is issued from Wikipedia - version of the 6/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.